Gout is a chronic joint disease associated with deposition of monosodium urate crystals, as a consequence of hyperuricemia. Gout is an intermittent flaring condition and acute gout flares are driven by NLRP3 inflammasome and IL1-beta production. However pathogenesis of acute gout flares remains poorly known in vivo in human. The aim of this study is to evaluate NLRP3 inflammasome activation in vivo in patients cells during acute gout flares.
Blood and synovial fluid will be obtained from remainder of patients' samples during an acute gout flares. White blood cells will be isolated and NLRP3 inflammasome activation will be assessed. Then, NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity.
Study Type
OBSERVATIONAL
Enrollment
10
Centre Hospitalier Saint Joseph Saint Luc
Lyon, France
RECRUITINGNLRP3 inflammasome activation in white blood cells.
White blood cells will be isolated from blood sample and NLRP3 inflammasome activation will be assessed by flow cytometry.
Time frame: Patient admission at hospital
NLRP3 inflammasome activation in synovial cells.
Nucleated cells will be isolated from synovial fluid sample and NLRP3 inflammasome activation will be assessed by flow cytometry.
Time frame: Patient admission at hospital
Effects of NLRP3 inflammasome inhibitors on proportion of NLRP3 inflammasome activation in white blood cells/synovial cells
NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity in blood or synovial fluid.
Time frame: up to 7 days after analysis of NLRP3 activity
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.